Results 1 to 10 of about 31,341 (158)

An Update on GLP‐1 Receptor Agonists [PDF]

Journal of Diabetes
Zachary Bloomgarden
doaj   +4 more sources

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Molecular Metabolism, 2021
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Aaron Novikoff, Shannon L. O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J. Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi, Matthias H. Tschöp, Brian Finan, Davide Calebiro, Timo D. Müller   +13 more
doaj   +3 more sources

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

Frontiers in Endocrinology, 2022
The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds
Weiting Hu, Rui Song, Rui Cheng, Caihong Liu, Rui Guo, Wei Tang, Jie Zhang, Qian Zhao, Xing Li, Jing Liu   +9 more
doaj   +3 more sources

GLP-1 receptor agonists and conscious sedation. [PDF]

Interv Pain Med
This FactFinder presents a brief summary of the evidence and outlines recommendations regarding periprocedural management of patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) therapy undergoing elective pain procedures under conscious sedation.
Holder EK, Ni A, Levi D, International Pain and Spine Intervention Society's Patient Safety Committee.   +3 more
europepmc   +3 more sources

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established
Hun Jee Choe, Young Min Cho
doaj   +1 more source

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions [PDF]

Kidney Research and Clinical Practice, 2022
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management.
Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo   +4 more
doaj   +1 more source

The benefits of GLP1 receptors in cardiovascular diseases

Frontiers in Clinical Diabetes and Healthcare, 2023
Glucagon like peptide-1 (GLP-1) receptor agonists are well established drugs for the treatment of type 2 diabetes (T2D). In addition to glycemic control, GLP-1 receptor agonists have beneficial other effects. They act by binding to GLP-1 receptors, which
Lamija Ferhatbegović, Denis Mršić, Amra Macić-Džanković   +2 more
doaj   +1 more source

Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy

American Heart Journal Plus, 2022
Select glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated cardiovascular benefits in both primary and secondary prevention populations and are recommended in multiple guidelines for cardiovascular risk reduction in people with type 2 ...
Elizabeth Van Dril, Margaret Allison, Christie Schumacher   +2 more
doaj   +1 more source

The Cardiovascular Effects of GLP‐1 Receptor Agonists [PDF]

Cardiovascular Therapeutics, 2010
SUMMARYGlucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety.
Okerson, Theodore, Chilton, Robert J
openaire   +2 more sources

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials

BMC Endocrine Disorders, 2022
Background The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists are still controversial in the treatment of type 2 diabetes mellitus (T2DM) patients.
Jing Qin, Li Song
doaj   +1 more source